NCT03870763 - Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

July 21, 2022

Study Completion Date

July 21, 2022

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Dimethyl Fumarate

Administered as specified in the treatment arm.

DRUG

Peginterferon Beta-1a

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (23)

333

Research Site, Taoyuan District

1083

Research Site, Budapest

10002

Research Site, Taipei

11315

Research Site, Tallinn

27607

Research Site, Raleigh

Unknown

Research Site, Medellín

Research Site, Ar Ramtha

Research Site, Petaling Jaya

Research Site, Seberang Jaya

Research Site, Guadalajara

Research Site, Morelia

Research Site, Santa Cruz

Research Site, Dammam

Research Site, Riyadh

Research Site, Bangkok

Research Site, Manouba

Research Site, Monastir

Research Site, Sfax

Research Site, Tunis

Research Site, Ankara

Research Site, Izmir

Research Site, Samsun

06351

Research Site, Seoul